指南与共识消化系统肿瘤

结直肠癌错配修复缺陷检测及年轻成人指南不依从性

Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults.
指南 / 共识 · JAMA Oncol · 2018-02-08

该研究利用美国国家癌症数据库分析2010-2012年诊断为浸润性结直肠腺癌的成人患者,评估错配修复缺陷检测的使用情况。结果显示总体检测率仅28.2%,年轻成人(<50岁)检测率为43.1%,均随时间有所上升但仍不理想,且多种因素与检测不足相关。

要点

  • 总体结直肠癌患者MMR缺陷检测率仅28.2%,年轻成人仅43.1%
  • 2010至2012年间检测比例上升,但绝对水平仍低
  • 高龄、非学术机构、未接受根治性手术等因素与检测不足相关

核心结论

  • 尽管指南推荐普遍检测,结直肠癌患者MMR缺陷检测总体使用率低,年轻成人中持续存在显著检测不足。

研究设计与样本

  • 研究利用美国国家癌症数据库,纳入2010年至2012年诊断为浸润性结直肠腺癌且已知MMR缺陷检测状态的成人患者。

主要发现

  • 较高教育水平(OR 1.38,95%CI 1.15-1.66)、较晚诊断年份(OR 1.81,95%CI 1.65-1.98)、早期疾病(OR 1.24,95%CI 1.18-1.30)和检查区域淋巴结数目≥12(OR 1.44,95%CI 1.34-1.55)与检测独立相关。
  • 高龄(OR 0.31,95%CI 0.26-0.37)、Medicare(OR 0.89,95%CI 0.84-0.95)、Medicaid(OR 0.83,95%CI 0.73-0.93)或无保险(OR 0.78,95%CI 0.66-0.92)、非学术机构(OR 0.44,95%CI 0.34-0.56)、直肠乙状结肠或直肠肿瘤(OR 0.76,95%CI 0.68-0.86)、未知分级(OR 0.61,95%CI 0.53-0.69)和未接受根治性手术(OR 0.33,95%CI 0.30-0.37)与检测不足相关。

临床怎么用

  • 在普遍检测时代,需针对检测不足的高风险人群(如高龄、非学术机构就诊、未手术者)实施干预以提高指南依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Mismatch repair (MMR) deficiency of DNA has been observed in up to 15% of sporadic colorectal cancers (CRCs) and is a characteristic feature of Lynch syndrome, which has a higher incidence in young adults (age, <50 years) with CRC. Mismatch repair deficiency can be due to germline mutations or epigenetic inactivation, affects prognosis and response to systemic therapy, and results in unrepaired repetitive DNA sequences, which increases the risk of multiple malignant tumors. OBJECTIVE: To evaluate the utilization of MMR deficiency testing in adults with CRC and analyze nonadherence to long-standing testing guidelines in younger adults using a contemporary national data set to help identify potential risk factors for nonadherence to newly implemented universal testing guidelines. DESIGN, SETTING, AND PARTICIPANTS: Adult (age, <30 to ≥70 years) and, of these, younger adult (<30 to 49 years) patients with invasive colorectal adenocarcinoma diagnosed between 2010 and 2012 and known MMR deficiency testing status were identified using the National Cancer Database. The study was conducted from March 16, 2016, to March 1, 2017. EXPOSURES: Patient sociodemographic, facility, tumor, and treatment characteristics. MAIN OUTCOMES AND MEASURES: The primary outcome of interest was receipt of MMR deficiency testing. Multivariable logistic regression was used to identify independent predictors of testing in adult and/or young adult patients. RESULTS: A total of 152 993 adults with CRC were included in the study (78 579 [51.4%] men; mean [SD] age, 66.9 [13.9] years). Of these patients, only 43 143 (28.2%) underwent MMR deficiency testing; the proportion of patients tested increased between 2010 and 2012 (22.3% vs 33.1%; P<.001). Among 17 218 younger adult patients with CRC, only 7422 (43.1%) underwent MMR deficiency testing; the proportion tested increased between 2010 and 2012 (36.1% vs 48.0%; P < .001). Irrespective of age, higher educational level (OR, 1.38; 95% CI, 1.15-1.66), later diagnosis year (OR, 1.81; 95% CI, 1.65-1.98), early stage disease (OR, 1.24; 95% CI, 1.18-1.30), and number of regional lymph nodes examined (≥12) (OR, 1.44; 95% CI, 1.34-1.55) were independently associated with MMR deficiency testing, whereas older age (OR, 0.31; 95% CI, 0.26-0.37); Medicare (OR, 0.89; 95% CI, 0.84-0.95), Medicaid (OR, 0.83; 95% CI, 0.73-0.93), or uninsured (OR, 0.78; 95% CI, 0.66-0.92) status; nonacademic vs academic/research facility type (OR, 0.44; 95% CI, 0.34-0.56); rectosigmoid or rectal tumor location (OR, 0.76; 95% CI, 0.68-0.86); unknown grade (OR, 0.61; 95% CI, 0.53-0.69); and nonreceipt of definitive surgery (OR, 0.33; 95% CI, 0.30-0.37) were associated with underuse of MMR deficiency testing. CONCLUSIONS AND RELEVANCE: Despite recent endorsement of universal use of MMR deficiency testing in patients with CRC and well-established guidelines aimed at high-risk populations, overall utilization of testing is poor and significant underuse of testing among young adults persists. Interventions tailored to groups at risk for nonadherence to guidelines may be warranted in the current era of universal testing.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Shaikh T, Handorf EA, Meyer JE, et al. Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol. 2018. PMID: 29121143. doi:10.1001/jamaoncol.2017.3580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。